Patients with celiac disease (CD) 12 do not tolerate gluten in their diet (1 ) . CD patients produce antibodies against gliadin and autoantibodies against histological structures called endomysium and its dominant antigen tissue transglutaminase (tTG). IgA-class antibodies against endomysium (EmA) and IgA-class antibodies against tTG (anti-tTG) have higher diagnostic accuracy than antibodies against native gliadin. Increased concentrations of IgA-class anti-tTG or EmA are an important indication for duodenal biopsy and subsequent histological confirmation of the diagnosis (1 ) . Normalization of anti-tTG and/or EmA concentrations after introduction of a gluten-free diet is a further criterion for diagnosis of CD (1 ) . However, CD is associated with selective IgA deficiency (sIgAD) (2 ) . To avoid false-negative serologic testing, IgA deficiency should be excluded in all patients suspected for CD. Two testing algorithms have been proposed: either all patients are screened for IgA deficiency (3 ) or total IgA is measured in only those patients with IgA-anti-tTG below an established cutoff (4, 5 ) . IgG antibodies against tTG (IgG-anti-tTG) have high diagnostic sensitivity for CD in IgA deficiency (6 -9 ) ; however, their diagnostic sensitivity in IgA-competent CD patients is low (10, 11 ) .
In addition to antibodies directed against native gliadin, assays for antibodies against deamidated gliadin (anti-dGli) have recently been described for serological diagnosis of CD (10 -16 ) . The immune response to dGli in IgA-competent CD patients was found not to be restricted to IgA, but could be demonstrated also for the IgG class of these antibodies (13, 15, 16 ) . Interestingly, in IgA-competent children, the IgG-anti-dGli appear to have a higher diagnostic accuracy than the respective IgA-anti-dGli (10, 11 ) . Assays for IgG-anti-dGli were superior to tests measuring antibodies to native gliadin and comparable in performance with IgA-anti-tTG in diagnosis of CD. A combination of the new test for IgG-anti-dGli with the assay of IgA-anti-tTG increases the fraction of patients in whom the diagnosis of CD can be confirmed or excluded with very high probability (10, 11 ) .
The high diagnostic accuracy of the IgG class of anti-dGli makes them a potential tool for diagnosis of CD in IgA-deficient patients. Recently, 8 IgA-deficient CD children were described (11, 17, 18 ) who all had low concentrations of IgA-anti-tTG and IgA-anti-dGli but high concentrations of IgG-anti-dGli. Two further studies, each including 20 IgA-deficient CD patients, revealed higher accuracy of IgG-anti-dGli detection compared with antibodies against native gliadin (9, 19 ) . However, IgG-anti-dGli did not achieve as high a diagnostic accuracy as IgG-anti-tTG. In this study, we retrospectively compared the IgG-anti-dGli test with IgG-anti-tTG and IgG-EmA assays using sera from 34 IgA-deficient CD patients ( Table 1) .
All sera were provided by the contributing clinicians without further selection. The patients included 24 children (mean age 10 years, range 2-16 years, 20 girls) and 10 adults (mean age 42 years, range 21-67 years, 7 women). Sera from 30 patients (Table 1) were obtained at time of diagnostic duodenal biopsy while on a normal (gluten-containing) diet. Also included were 4 celiac patients with dietary transgressions (gluten-containing diet despite recommendations). Diagnosis was based on histological analysis of duodenal biopsies performed according to the revised criteria of the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition (1 ). Intestinal pathology of all patients was in accordance with Marsh II/III criteria. The concentration of total IgA, measured nephelometrically, was Ͻ0.05 g/L in 29 patients, and defined as sIgAD. In the other 5 patients, IgA concentrations were below age-specific cutoffs, but Ͼ0.05 g/L (patients with low IgA concentrations). We also investigated 6 subjects (3 female, 3 male; 3 children, 3 adults) with sIgAD and normal biopsy (no CD) as controls. All patients gave informed consent. The study protocol was approved by the Ethics Committee of the Medical Faculty of the University of Leipzig.
In all sera, we measured both IgA-and IgG-class anti-dGli, anti-tTG, and EmA by means of commercially available test systems (Euroimmun). We measured anti-dGli by anti-gliadin (GAF-3X)-ELISA (detects antibodies reactive to deamidated gliadinanalogous fusion peptides composed of 3 repetitive dimers representing synthetic analogs of deamidated gliadin nonapeptides) (10 ); anti-tTG by antitissue transglutaminase ELISA, coated with recombinant insect cell-expressed tTG; and EmA by indirect immunofluorescence analysis using a combination of primate esophagus, primate small intestine, and primate liver. Diagnostic sensitivity was calculated using (1) age-specific cutoffs for 95% specificity, derived from 316 biopsy-controlled children without CD as reported (11 ) and 400 adult blood donors, and (2) cutoffs proposed by the manufacturer of each test kit. We computed 95% CIs according to the modified Wald method.
Irrespective of the different cutoffs, none of the 34 IgA-deficient CD patients was positive for IgA-antitTG, IgA-EmA, or IgA-anti-dGli. All 3 IgG-based assays (IgG-anti-tTG, IgG-EmA, IgG-anti-dGli) were negative for only 1 patient ( These results show that the diagnostic sensitivity of IgG-anti-dGli is comparable with that of IgG-antitTG for CD in IgA deficiency. Assays of IgG-anti-tTG and IgG-anti-dGli appear important not only for avoiding false-negativity in sIgAD, but also in patients with low IgA concentrations. These assays may also detect IgA-deficient patients in dietary transgressions (Table 1 ). Among the 6 control subjects with sIgAD (no CD), the concentrations of IgG-anti-tTG and IgGanti-dGli were within the reference range (data not shown).
Our results show that IgG-anti-dGli are valid markers for CD in IgA deficiency. The high diagnostic sensitivity obtained with the IgG-anti-dGli assay is comparable with results of previous smaller studies on IgA-deficient CD patients (9, 19 ) and with reports on individual IgA-deficient cases (17, 18 ) applying another test based on dGli as the antigen.
It is worth mentioning that not only sIgAD can cause false-negative test results in IgA-based assays; they may also occur in patients with low age-specific IgA concentrations, which do not strictly fulfill the criteria of sIgAD.
IgA deficiency does not always cause falsenegative IgA-autoantibody concentrations in CD (3, 20 ) . Our IgA-deficient patient group comprised only individuals with low IgA-anti-tTG concentration. This represents a bias, since patients with low total IgA but increased (true-positive) IgA-anti-tTG were not considered. The retrospective nature of our study and the nonsequential character of our data may represent further sources of bias.
The IgG-anti-dGli test has high diagnostic sensitivity not only in IgA-competent but also in IgAdeficient CD patients. This is in contrast to the IgGanti-tTG assay, which is specific for CD only in IgA deficiency. As recently described (11 ) in IgA-competent CD children, the 96% diagnostic sensitivity (at 95% specificity) of IgG-anti-dGli is comparable to that of IgA-anti-tTG (also 96%) but substantially higher than that of IgG-anti-tTG (62%). Use of manufacturer cutoffs maintained this relationship (11 ) .
We conclude that increased concentrations of IgG-anti-tTG are informative only after estimation of total IgA. However, IgG-anti-dGli specifically indicate CD irrespective of total IgA concentration. Therefore, a combined evaluation of IgA-anti-tTG and IgG-antidGli, as already suggested for IgA-competent CD (10, 11, 16 ) , seems to be adequate for serodiagnosis of CD irrespective of IgA deficiency and without the need for estimating total IgA concentrations.
Inspection of duodenal biopsy remains the gold standard in CD diagnosis (1 ) . IgA-deficient symptomatic patients with negative serological tests (such as patient 8, Table 1 ) should undergo duodenal biopsy for evaluation of CD and other intestinal diseases associated with IgA deficiency.
